Abstract:The insulin/IGF-1 signaling (IIS) regulates a wide range of biological processes, including aging and lifespan, and has also been implicated in the pathogenesis of Alzheimer's disease (AD). We and others have reported that reduced signaling by genetic ablation of the molecules involved in IIS (e.g., insulin receptor substrate 2 [IRS-2]) markedly mitigates amyloid plaque formation in the brains of mouse models of AD, although the molecular underpinnings of the amelioration remain unsolved. Here, we revealed, by a transcriptomic analysis of the male murine cerebral cortices, that the expression of genes encoding extracellular matrix (ECM) was significantly upregulated by the loss of IRS-2. Insulin signaling activity negatively regulated the phosphorylation of Smad2 and Smad3 in the brain, and suppressed TGF-β/Smad-dependent expression of a subset of ECM genes in brain-derived cells. The ECM proteins inhibited Aβ fibril formation in vitro, and IRS-2 deficiency suppressed the aggregation process of Aβ in the brains of male APP transgenic mice as revealed by injection of aggregation seeds in vivo Our results propose a novel mechanism in AD pathophysiology whereby IIS modifies Aβ aggregation and amyloid pathology by altering the expression of ECM genes in the brain.SIGNIFICANCE STATEMENT The insulin/IGF-1 signaling (IIS) has been recognized as a regulator of aging, a leading risk factor for the onset of Alzheimer's disease (AD). In AD mouse models, genetic deletion of key IIS molecules markedly reduces the amyloid plaque formation in the brain, although the molecular underpinnings of this amelioration remain elusive. We found that the deficiency of insulin receptor substrate 2 leads to an increase in the expression of various extracellular matrices (ECMs) in the brain, potentially through TGF-β/Smad signaling. Furthermore, some of those ECMs exhibited the potential to inhibit amyloid plaque accumulation by disrupting the formation of Aβ fibrils. This study presents a novel mechanism by which IIS regulates Aβ accumulation, which may involve altered brain ECM expression.

Characteristics of Insulin-degrading Enzyme in Alzheimer's Disease: A Meta-Analysis.

Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease.

Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer’s disease: possible mechanisms of IDE in T2D and AD

Degradation of Alzheimer’s Amyloid-β by a Catalytically Inactive Insulin-Degrading Enzyme

Expression and Functional Profiling of Neprilysin, Insulin‐degrading Enzyme, and Endothelin‐converting Enzyme in Prospectively Studied Elderly and Alzheimer’s Brain

Insights into Non-Proteolytic Inhibitory Mechanisms of Polymorphic Early-Stage Amyloid β Oligomers by Insulin Degrading Enzyme

Role of Aβ-degrading enzymes in pathogenesis and treatment of Alzheimer's disease

Deregulation of Brain Insulin Signaling in Alzheimer’s Disease

Effect of Berberine Chloride on Expression of Insulin Degrading Enzyme in Rat Models with AD

Investigation of amyloid‑β peptide production and clearance pathways in different stages of Alzheimer's disease

Insulin Signaling in Sporadic Alzheimer's Disease.

Structures of Human Insulin-Degrading Enzyme Reveal a New Substrate Recognition Mechanism

Targeting Insulin Signaling for the Treatment of Alzheimer's Disease.

Insulin-degrading enzyme sorting in exosomes: a secretory pathway for a key brain amyloid-beta degrading protease.

Serum insulin degrading enzyme level and other factors in type 2 diabetic patients with mild cognitive impairment

Level of Fasting Plasma Glucose, True Insulin, C-peptide and Amyloid Beta-protein in Patients with Alzheimer Disease

Down‐regulation of Insulin‐degrading Enzyme by Presenilin 1 V97L Mutant Potentially Underlies Increased Levels of Amyloid Beta 42

Effects of 4-Hydroxy-nonenal and Amyloid-Beta on Expression and Activity of Endothelin Converting Enzyme and Insulin Degrading Enzyme in Sh-Sy5y Cells

Insulin‐degrading enzyme: an ally against metabolic and neurodegenerative diseases

Genetic Reduction of Insulin Signaling Mitigates Amyloid-β Deposition by Promoting Expression of Extracellular Matrix Proteins in the Brain

The autocrine regulation of insulin-like growth factor-1 in human brain of Alzheimer’s disease